Further growth for Boyds’ specialist Regulatory Operations team

Global drug development consultancy Boyds has announced the appointment of Lisa Allenby as Associate Director, Regulatory Operations.

Lisa has more than 25 years’ experience in regulatory operations, having previously worked at DLRC Regulatory Consultancy and pharmaceutical company Mylan. She has extensive experience of managing major filings across the globe, as well as leading cross-functional meetings representing regulatory operations in the submissions management process.

Lisa also has experience working with SMEs on key projects with the Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).

At Boyds, Lisa will be responsible for assisting clients with Investigational New Drug (IND) applications and developing the Regulatory Operations team and department.

Boyds’ in-house Regulatory Operations service was launched in 2023 to enable the company to support the full lifecycle of its clients’ drug development projects.

Lisa comments: “I am delighted to be joining the team at Boyds. Having previously worked with Michelle Hackney, we’ve built a strong and effective working relationship – something that is critical in our field, where projects are often time-critical and demand a high level of trust and quality. This is an exciting opportunity to contribute to the growth and development of Boyds’ in house regulatory operations service, and to showcase the value of its highly specialist, efficient approach.”

Michelle Hackney, Associate Director, Regulatory Operations, adds: “We are thrilled to welcome Lisa to the team. Her regulatory operations expertise will be a real asset, enhancing the breadth of experience within our department and further strengthening Boyds’ overall service offering. Since launching our Regulatory Operations service, we’ve seen strong demand for our expertise in submission management. With Lisa now on board, we’re looking forward to building on this momentum, leveraging our collective experience to accelerate our clients’ drug development journeys.”

Boyds was established in 2005 by Professor Alan Boyd and provides specialist consultancy services to a global client base, supporting the development of new, cutting-edge medicines for patient benefit.  

For more information, please visit: www.boydconsultants.com